Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.

Genes - 6 Aug 2022

Goebel Emily A, Kerkhof Jennifer, Dzyubak Oleksandra, McLachlin C Meg, McGee Jacob, Sadikovic Bekim

Abstract excerpt

Despite advances in treatment, prognosis for most patients with high-grade serous carcinoma (HGSC) remains poor. Genomic alterations in the homologous recombination (HR) pathway are used for cancer risk assessment and render tumours sensitive to platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitors (PARPi), which can be associated with more favourable outcomes. In addition to patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ Cells

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36011309
DOI: 10.3390/genes13081398
PMCID: PMC9407448

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.PMID 36011309Read ↗

Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.Semantic proximity Read ↗

Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.Semantic proximity Read ↗

High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancerSemantic proximity Read ↗

The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.Semantic proximity Read ↗

Cancer genomic profiling predicts pathogenicity of BRCA1 and BRCA2 variantsSemantic proximity Read ↗

Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board.Semantic proximity Read ↗

BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report.Semantic proximity Read ↗

Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate CancerSemantic proximity Read ↗

Homologous recombination deficiency-driven genomic instability in ovarian cancer as an indicator of BRCA1 and BRCA2 variant pathogenicity.Semantic proximity Read ↗

Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.Semantic proximity Read ↗

Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groups.Semantic proximity Read ↗

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.